Psoriatic patients underdiagnosed, undertreated for hypertension and dyslipidaemia
There appear to be several patients with psoriasis and psoriatic arthritis (PsA) who are underdiagnosed and undertreated for hypertension and dyslipidaemia in actual situations, a recent study has found.
Overall, 2,254 patients (58.9 percent PsA; 41.1 percent psoriasis; mean age 52 years; 53 percent men) from eight centres in Canada, Israel and the United States were included in this study.
Of the participants, 87.6 percent had at least one modifiable cardiovascular risk factor (CVRF), 45.1 percent had hypertension, 49.4 percent dyslipidaemia, 13.3 percent diabetes, 75.3 percent were overweight or obese, 54.3 percent had central obesity, and 17.3 percent were current smokers.
There were 59.2 percent and 65.6 percent of patients with hypertension and dyslipidaemia, respectively, who were undertreated. Moreover, undertreatment correlated with younger age (≤50 years), having psoriasis and male sex.
To estimate the number of underdiagnosis and undertreatment of CVRF in an international multicentre cohort of patients with psoriasis and PsA, researchers conducted a cross-sectional of patients with psoriatic disease form the International Psoriasis and Arthritis Research Team cohort. They determined the presence of modifiable CVRF (diabetes, hypertension, dyslipidaemia, smoking, elevated body mass index and central obesity) and the use of appropriate therapies for hypertension and dyslipidaemia.
The Framingham Risk Score was used to calculate the 10-year CV risk. Physician adherence with guidelines for the treatment of hypertension and dyslipidaemia was also evaluated. Finally, researchers used regression analysis to assess predictors of undertreatment of hypertension and dyslipidaemia.
“Strategies to improve the management of CVRF in psoriatic patients are warranted,” according to researchers.